Merck Gets Positive EU Opinion to Expand ENFLONSIA Use for Young Children
Nov 13 (Reuters) - Merck & Co Inc MRK.N:
MERCK RECEIVES POSITIVE EU CHMP OPINION TO EXPAND MARKETING AUTHORIZATION FOR ENFLONSIA® (CLESROVIMAB) TO INCLUDE CHILDREN UP TO 24 MONTHS OF AGE WHO REMAIN VULNERABLE TO SEVERE RSV DISEASE THROUGH THEIR SECOND RSV SEASON
MERCK: FINAL EU COMMISSION DECISION ON ENFLONSIA EXPANSION EXPECTED WITHIN TWO MONTHS
Further company coverage: MRK.N